We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS Will Withdraw Istodax for PTCL After Disappointing Confirmatory Trial
BMS Will Withdraw Istodax for PTCL After Disappointing Confirmatory Trial
Bristol Myers Squibb (BMS) said it plans to withdraw Istodax’s indication as a monotherapy for peripheral T-cell lymphoma (PTCL) after at least one prior therapy.